Stock Worth Watching: What’s Ahead for Adaptimmune Therapeutics PLC – ADR After Achieving 1 Year Low?

Stock Worth Watching: What's Ahead for Adaptimmune Therapeutics PLC   ADR After Achieving 1 Year Low?

The stock of Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) hit a new 52-week low and has $3.56 target or 10.00% below today’s $3.95 share price. The 9 months bearish chart indicates high risk for the $267.39M company. The 1-year low was reported on Nov, 3 by Barchart.com. If the $3.56 price target is reached, the company will be worth $26.74M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 60,732 shares traded hands. Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) has declined 49.88% since April 1, 2016 and is downtrending. It has underperformed by 51.09% the S&P500.

Analysts await Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) to report earnings on November, 11. They expect $-0.23 EPS, down 1,050.00% or $0.21 from last year’s $-0.02 per share. After $-0.31 actual EPS reported by Adaptimmune Therapeutics PLC – ADR for the previous quarter, Wall Street now forecasts -25.81% EPS growth.

Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) Ratings Coverage

Out of 2 analysts covering Adaptimmune Therapeutics PLC (NASDAQ:ADAP), 1 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 50% are positive. Adaptimmune Therapeutics PLC has been the topic of 2 analyst reports since February 25, 2016 according to StockzIntelligence Inc. The stock of Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) earned “Underperform” rating by Bank of America on Monday, October 24. As per Thursday, February 25, the company rating was initiated by Citigroup.

According to Zacks Investment Research, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.”

More news for Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) were recently published by: Marketwatch.com, which released: “Adaptimmune Therapeutics PLC ADR” on April 14, 2015. Quotes.Wsj.com‘s article titled: “DOW JONES, A NEWS CORP COMPANY” and published on November 29, 2014 is yet another important article.

ADAP Company Profile

Adaptimmune Therapeutics plc, incorporated on December 03, 2014, is a clinical-stage biopharmaceutical company. The Firm is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Firm has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Firm develops TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: ,

Related posts

Leave a Comment